Researchers have revealed that innovative Lifileucel, which is used once, and harnesses the patient’s immune system to combat advanced skin cancer, may help people live longer.
Treatment is dependent on the tumor-infiltating lymphocyte, and includes the isolation of T cells-a type of white blood cell-from tumors and cultivation in the laboratory before they are injected into the patient where they can recognize and combat cancer.
The study was conducted by researchers from the Royal Marsden Foundation of the UK Health Services and the Cancer Center at the University of Colorado in the United States, and its results were presented at the annual meeting of the American Society of Clinical ONCOLOGY (SOCIETY OF ONCOLOGY), which was held in Chicago between May 30 until June 3, and wrote about it, and wrote about it, and wrote about it, and wrote about it, and wrote about it from May 30 until June 3, and wrote about it, and wrote about it. British Independent.
The study included 153 patients from Europe and the United States, and experts say it may become an option for advanced melanoma patients (one of the types of skin cancer), or melanoma in its fourth stage, where the disease spreads to other parts of the body.
One in every 5 patients with advanced skin cancer (19.7%) remained for a period of 5 years alive after receiving Leviliusil, with tumors shrinkage in most cases. The experiment found that the tumors shrunk in nearly 4 out of every 5 patients (79.3%).
A revolution in cancer treatment
Dr. Andrew Forenes, a consultant medical oncology who led the experiment at the Royal Marsen Foundation of the National Health Services Authority, said that although the current forms of immunotherapy “have revolutionized cancer treatment in recent years, they generally benefit a minority of treated patients instead of the majority of them.”
“The results of this experiment showed that the treatment of lymphocytes to the tumor may change expectations for people with advanced melanoma,” he added.
Experiments are also looking to use the treatment with lymphocytes to the tumor with Pembrolizumab for people with advanced skin cancer.
Pimberzomeb works by targeting and blocking a protein known as “PD-L1” (PD-L1), and is found in T-cells to help the immune system to combat cancer more effectively.
“We continue our research on the use of the treatment with lymphocytes to the tumor, in addition to other forms of cellular therapy, through a broader set of cancer, including advanced sub -species of lung, liver, ovary, skin and testicle, as well as soft tissue sarcoma,” Dr. Forenes added.
“The study shows that for patients who have limited options, one dose of Levilosel can provide a deep and permanent response, and even a complete recovery in some cases. This represents great progress in our way of thinking about treating solid tumors,” said James Larkin, co -author of the study, a medical oncology consultant at Royal Marsen Hospital and professor of microscopic cancer treatments at the UK Cancer Research Institute.